India, Nov. 17 -- Shares of SELLAS Life Sciences Group, Inc. (SLS) surged 175% on Tuesday after the biopharmaceutical company announced positive topline results from its pivotal Phase 3 REGAL trial of its investigational cancer vaccine, galinpepimut-S (GPS), in patients with acute myeloid leukemia (AML).

The stock is trading at $20.54, up $13.07 or 174.97%. It opened at $24.00 after closing the previous session at $7.47. The stock has traded between $1.39 and $24.89 over the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Published by HT Digital Content Services with permission from RTT News....